DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

Group 1 - DOMA Perpetual Capital Management LLC owns approximately 4.14% of Pacira BioSciences, Inc.'s outstanding shares and intends to nominate four independent director candidates at the 2025 annual meeting [1] - DOMA believes in the significant value of Pacira's intellectual property and asserts that the company's stock is grossly undervalued, urging the company to initiate a stock tender offer for 10 million shares using its cash reserves [1] - The company has a healthy and growing free cash flow, which supports the execution of its already-approved $150 million buyback program [1] Group 2 - DOMA Perpetual Capital Management LLC is based in Miami, Florida, and focuses on identifying attractive companies with sustainable competitive advantages while limiting downside risks [2] - The firm employs an opportunistic, fundamentals-based investment strategy across various sectors and market caps globally [2] Group 3 - DOMA and its affiliates plan to file a preliminary proxy statement with the SEC to solicit votes for their director nominees at Pacira's 2025 annual meeting [3] - Stockholders are advised to read the proxy statement and other materials as they will contain important information [4]